OTX-2002 + TYROSINE KINASE INHIBITOR TWO

OTX-2002 + TYROSINE KINASE INHIBITOR TWO is a **combination investigational therapy** composed of OTX-2002, a first-in-class programmable mRNA-based epigenomic controller, together with a tyrosine kinase inhibitor (TKI) referenced as "TYROSINE KINASE INHIBITOR TWO". OTX-2002 acts by delivering an mRNA encoding zinc finger-based proteins that epigenetically repress MYC gene expression in tumor cells, especially in hepatocellular carcinoma (HCC)[1][2][3][4][5]. The MYC oncogene is a key driver of cancer proliferation, and its downregulation leads to reduced tumor growth, apoptosis, and sustained antitumor effects. TKIs, including drugs like sorafenib and lenvatinib, target multiple tyrosine kinases that drive cell proliferation and survival; when combined with OTX-2002, synergistic or additive antitumor activity has been observed in preclinical HCC models[1][3][5]. OTX-2002 is administered via intravenous lipid nanoparticle delivery, and the combination aims to address therapeutic resistance and improve efficacy in patients with MYC-driven malignancies, primarily HCC[1][3][5]. Omega Therapeutics is the developer of OTX-2002, and it is being studied clinically both as monotherapy and in combinations, including with TKIs[3][5][6].